Archean Chemical Industries (ACI) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue declined to INR 2,234 million, a 37% year-over-year drop, mainly due to logistics challenges impacting exports and dispatches.

• Export markets contributed 72% of revenue, with bromine and industrial salt accounting for 55% and 44% of total revenue, respectively.

• FY24 revenue was INR 13,762.8 million, maintaining leadership in Indian bromine merchant sales and as the largest exporter of bromine and industrial salt.

• Unaudited standalone and consolidated financial results for Q1 FY25 were approved and reviewed by the Audit Committee and Board of Directors on August 2, 2024.

• Appointment of Mr. N R Kannan as Executive Director and Mr. Ravi Prakash Mundhra as Company Secretary and Compliance Officer, both effective August 2, 2024.

Financial highlights

• Q1 FY25 EBITDA was INR 849 million, with a margin of 38%.

• Net profit after tax for Q1 FY25 was INR 484.6 million, with basic EPS at INR 3.93.

• Standalone revenue from operations for Q1 FY25 was ₹21,116.33 lakhs, with consolidated revenue at ₹21,269.20 lakhs.

• Standalone profit after tax for Q1 FY25 was ₹4,846.22 lakhs; consolidated profit after tax was ₹4,484.17 lakhs.

• Salt revenue was INR 1,172 million, bromine INR 937 million, and SOP INR 22 million.

Outlook and guidance

• Bromine production guidance for FY25 is 22,000–25,000 metric tons, slightly revised down for conservatism.

• Salt segment expected to recover as logistics normalize; annual volume guidance remains unchanged.

• Acume (bromine derivatives) sales expected to ramp up in H2 FY25, with 10 client approvals and more in progress.

• Commissioned Phase 1 of new bromine derivatives capacity at Jhagadia, GIDC, expected to enhance product offerings and support growth.

• Oren Hydrocarbons acquisition to contribute from H2 FY25, with phased plant commissioning and initial focus on starch and barytes.